RobertPGiuglianoMD

Preventive Cardiology, Cardiac Critical Care

Cardiovascular Medicine Brigham and Women's Hospital

Dr. Giugliano is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
TIMI Study Office, Hale BTM Suite 7022, 60 Fenwood Road
Brigham And Womens Hospital Cardiovascualar Division
Boston, MA 02115
Phone+1 617-278-0317

Fax+1 617-264-5130

PubMed

Unsupervised clustering approach to assess heterogeneity of treatment effects across patient phenotypes in randomized clinical trials.
Andrea Bellavia, Xinhui Ran, Andre Zimerman, Elliott M Antman, Robert P Giugliano
Contemporary Clinical Trials. 2024-12-13
1 citations
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF.
Paul M Haller, Petr Jarolim, Michael G Palazzolo, Andrea Bellavia, Elliott M Antman
Journal of the American College of Cardiology. 2024-10-15
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.
Linda S Johnson, Alexander P Benz, Ashkan Shoamanesh, John W Eikelboom, Michael Ezekowitz
Journal of the American Heart Association. 2024-09-03

Journal Articles

Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction with Statins, Ezetimibe, and PCSK9 Inhibition
Robert P Giugliano, Marc S Sabatine, JAMA Cardiology
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin Therapy
Prakash Deedwania, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial Infarction
Christopher E Kurtz, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology

Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
The Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score, Cardiovascular Risk Stratification and a Strategy for Secondary Prevention with EzetimibeMay 2018
Oral Anticoagulation in Patients with Liver DiseaseMarch 2018
Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
Join now to see all

Association Between Changes in Serial Values of hsTn, Subsequent Cardiovascular EventsJanuary 23rd, 2023
New Analysis Finds Broader Benefit for Post ACS Ezetimibe-Statin ComboOctober 5th, 2021
Post-ACS Patients with Low LDL Levels Remain at Risk: IMPROVE-ITOctober 4th, 2021
Join now to see all